Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

詳細記述

書誌詳細

主要な著者:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2017-06-01
シリーズ:	Blood Advances
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!